High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study
- 30 August 2012
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (3) , 658-661
Abstract
Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem cell disorder, frequently reported in elderly patients, classified as a myelodysplastic/ myeloproliferative neoplasm by the 200...Keywords
This publication has 14 references indexed in Scilit:
- Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: A case series and literature reviewLeukemia Research, 2012
- Transient Low Doses of DNA-Demethylating Agents Exert Durable Antitumor Effects on Hematological and Epithelial Tumor CellsCancer Cell, 2012
- TET2 Mutations Are Associated with Specific 5-Methylcytosine and 5-Hydroxymethylcytosine Profiles in Patients with Chronic Myelomonocytic LeukemiaPLOS ONE, 2012
- Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trialBlood, 2011
- Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-AzacytidineLeukemia, 2011
- Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasLeukemia, 2011
- Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2Nature, 2010
- Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemiaCancer, 2007
- Prognostic factors and risk assessment in chronic myelomonocytic leukemia: Validation study of the M.D. Anderson Prognostic Scoring SystemLeukemia & Lymphoma, 2007
- Decitabine improves patient outcomes in myelodysplastic syndromesCancer, 2006